Reference standard for prescription omega-3-acid ethyl esters
Leading the omega-3 pharma market
- Post-myocardial infarction
Over two decades ago BASF introduced to the market Omacor®/Lovaza™, the first FDA and EU approved omega-3 based prescription drug. Our product is now represented in over 80 countries. We became world leaders in high-concentrate Omega-3 fatty acids for pharmaceuticals.
Prescription omega-3s are shown to improve:
We offer generic omega-3-acid ethyl esters (K85EE) as an Active Pharmaceutical Ingredient (API).